Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNovo Nordisk A/S Class B

Novo Nordisk A/S Class B

PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2026-10-28T03:30:06.133753Z
Market Cap
19895.49M
P/E
0.39

Momentum Score

…

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
217.06
Low
509.66
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Novo Nordisk is a global pharmaceutical company focused on diabetes, obesity and related chronic disease treatments, producing insulin and GLP-1 therapies alongside other specialty medicines. Rising prevalence of diabetes and obesity, ongoing GLP-1 program development and scale in manufacturing and global distribution are key long-term growth drivers that may benefit revenues and margins. Investors may find the company attractive because it appears positioned with a leading market share in chronic care, steady cash generation and a record of returning capital to shareholders.
Primary risks include heavy reliance on a small number of blockbuster therapies exposing the company to competitive pressure from other GLP-1 and obesity drug makers, regulatory and pricing scrutiny, and potential safety or supply disruptions that could materially affect sales.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
260.40
Dividend Yield
1.69%
Revenue TTM
201325.00M
Revenue Per Share
89.38
Gross Profit TTM
148506.00M
Debt / Equity
0.18
ROE
81.54%
Net Debt
-
ROCE
62.47%
Diluted EPS TTM
21.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax 59080.00M 53130.00M 48553.00M 47615.00M 48680.00M
Net income 47757.00M 42138.00M 38951.00M 38628.00M 38130.00M
Selling general administrative 40409.00M 36108.00M 35301.00M 33656.00M 32384.00M
Gross profit 117142.00M 106014.00M 102462.00M 94214.00M 94064.00M
Ebit 59341.00M 54476.00M 52483.00M 47248.00M -
Operating income 58644.00M 54126.00M 52483.00M 47248.00M 48967.00M
Other operating expenses 456.00M 460.00M 600.00M 1152.00M -
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Tax provision 11323.00M 10992.00M 9602.00M 8987.00M 10550.00M
Interest income 558.00M 846.00M 3757.00M 439.00M 219.00M
Income tax expense 11323.00M 10992.00M 9602.00M 8987.00M -
Total revenue 140800.00M 126946.00M 122021.00M 111831.00M 111696.00M
Cost of revenue 23658.00M 20932.00M 19559.00M 17617.00M 17632.00M
Net income applicable to common shares 47757.00M 42138.00M 38951.00M 38628.00M 38130.00M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 194508.00M 144922.00M 125612.00M 110769.00M 102355.00M
Intangible assets 38825.00M 20657.00M 5835.00M 5145.00M 3325.00M
Other current assets 1690.00M 2332.00M 188.00M 204.00M 2304.00M
Total liab 123762.00M 81597.00M 68019.00M 58930.00M 52540.00M
Total stockholder equity 70746.00M 63325.00M 57593.00M 51839.00M 49815.00M
Other current liab 26395.00M 57097.00M 51151.00M 46893.00M -
Common stock 462.00M 470.00M 480.00M 490.00M 500.00M
Retained earnings 72004.00M 63774.00M 57817.00M 53406.00M 48855.00M
Other liab 11285.00M 8427.00M 6027.00M 4766.00M -
Good will 4346.00M - - - -
Other assets 8939.00M 6539.00M 4962.00M 2893.00M 1941.00M
Total current liabilities 99516.00M 70273.00M 58983.00M 54164.00M 47056.00M
Short term debt 12862.00M 6684.00M 659.00M 515.00M 1694.00M
Short long term debt total 12961.00M 2897.00M 3009.00M - -
Other stockholder equity -1714.00M -911.00M -694.00M -2046.00M 471.00M
Property plant equipment 55362.00M 50269.00M 50551.00M 41891.00M 35247.00M
Total current assets 85595.00M 65809.00M 62456.00M 59067.00M 60080.00M
Net tangible assets 27575.00M 42668.00M 51758.00M 46694.00M -
Short term investments 6765.00M - - - -
Net receivables 46799.00M 32184.00M 29152.00M 26889.00M 20165.00M
Long term debt 9654.00M - - - -
Inventory 19621.00M 18536.00M 17641.00M 16336.00M 15373.00M
Accounts payable 8870.00M 5717.00M 6358.00M 6756.00M -
Treasury stock -6.00M -8.00M -10.00M -11.00M -11.00M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments -5941.00M -380.00M -299.00M 298.00M -
Change to liabilities 3153.00M -641.00M -398.00M 1146.00M -
Total cashflows from investing activities -31605.00M -22436.00M -11509.00M -12080.00M -6571.00M
Net borrowings 15471.00M 4732.00M -741.00M 94.00M -
Total cash from financing activities -25493.00M -32244.00M -35484.00M -34521.00M -35689.00M
Change to operating activities 2185.00M 5.00M 441.00M -932.00M -
Net income 47757.00M 42138.00M 38951.00M 38628.00M 38130.00M
Change in cash -1507.00M -3185.00M -218.00M -1529.00M -1303.00M
Total cash from operating activities 55000.00M 51951.00M 46782.00M 44616.00M 41168.00M
Depreciation 5111.00M 5069.00M 4679.00M 3925.00M 3182.00M
Other cashflows from investing activities 4.00M 18.00M 20.00M 19.00M 2077.00M
Dividends paid 21517.00M 20121.00M 19409.00M 19048.00M 18844.00M
Change to inventory -1085.00M -895.00M -1305.00M -963.00M -
Change to account receivables -12909.00M -2822.00M -2126.00M -2621.00M -
Sale purchase of stock -19447.00M -16855.00M -15334.00M -15567.00M -16845.00M
Change to netincome 10588.00M 8890.00M 6540.00M 5433.00M -
Capital expenditures 6335.00M 5825.00M 8932.00M 9636.00M 8648.00M
Change in working capital -23114.00M -14781.00M -14464.00M -12610.00M -12721.00M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Novo Nordisk A/S Class B

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Allé 1, Bagsvaerd, Denmark, 2880

45 44 44 88 88

https://www.novonordisk.com

59337

Name Title Year Born
Mr. Lars Fruergaard Jorgensen Pres, CEO & Member of Management Board 1966
Mr. Karsten Munk Knudsen Exec. VP, CFO & Member of the Management Board 1971
Mr. Henrik Ehlers Wulff Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board 1970
Ms. Camilla Sylvest Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board 1972
Dr. Martin Holst Lange Exec. VP, Head of Devel. & Member of the Management Board 1970
Ms. Monique Carter Exec. VP, Head of People & Organisation and Member of Management Board 1973
Dr. Marcus Schindler Ph.D. EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board 1966
Mr. Maziar Mike Doustdar Exec. VP, Head of International Operations & Member of the Management Board 1970
Mr. Douglas J. Langa Exec. VP, Head of North America Operations & Member of Management Board 1966
Mr. Ludovic Helfgott Exec. VP, Head of Rare Disease & Member of Management Board 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…